Moses Lake Professional Pharmacy (JD & SN Inc.), Moses Lake, WA

Is Moses Lake Professional Pharmacy (JD & SN Inc.) registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.

Does Moses Lake Professional Pharmacy (JD & SN Inc.) hold a Washington pharmacy license?

State board of pharmacy records for Washington are not checked: the Department of Health’s open dataset on data.wa.gov lists individual credentials but not pharmacy licenses, and its enforcement column has been removed for now; the department’s provider search is an interactive search, which this index does not use.

Has Moses Lake Professional Pharmacy (JD & SN Inc.) had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 state referral letter (Aug 23, 2023) and 1 FMD-145 letter (Aug 23, 2023) for Moses Lake Professional Pharmacy (JD & SN Inc.). State board of pharmacy records for Washington are not checked: the Department of Health’s open dataset on data.wa.gov lists individual credentials but not pharmacy licenses, and its enforcement column has been removed for now; the department’s provider search is an interactive search, which this index does not use. The state referral and handoff letters above are FDA’s letters to the state, not board actions.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
JD & SN Inc.; Moses Lake Professional Pharmacy
Location
Moses Lake, WA
Type as FDA labels it
503A
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
1
Warning letters on FDA’s actions page
0
Latest action on that page
Aug 23, 2023
FDA Data Dashboard inspections
2 inspections: 1 OAI, 1 VAI; 4 published Form 483s
Form 483 text on this page
2 Form 483s, 2 observations
State board records
Not checked

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as JD & SN Inc. (dba Moses Lake Professional Pharmacy), a 503A facility, with 3 dated actions.

Document
Aug 23, 2023State referral letterState Referral Letter Issued 8/23/2023Not linked by FDA
Aug 23, 2023FMD-145 letterFMD-145 Issued 8/23/2023Not linked by FDA
Apr 4, 2023Form 483483 Issued 04/04/2023FDA copy (archived)

A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists JD & SN Inc., Moses Lake, WA (FEI number 3004603767), matched to this page by exact name, city and state. It lists 2 inspections: 1 OAI, 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Apr 4, 2023Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30046037671201924
Jul 21, 2015Official Action Indicated (OAI)Drug Quality Assurance (Drugs)3004603767935807

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483s for this site have 2 numbered observations in all, across 2 inspections ending Jul 12, 2017 to Apr 4, 2023. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Mar 20, 2023 to Apr 4, 2023: 1 observation

Firm on the cover
JD & SN Inc., 1555 Pilgrim St, Moses Lake, WA 98837-4623
FEI number
3004603767
Establishment type on the cover
Producer of Non-Sterile Drug Products
FDA district office on the cover
22215 26th Ave SE Suite 210 Bothell, WA 98021
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

You produced hazardous drugs without providing adequate cleaning of work surfaces and cleaning of utensils to prevent cross-contamination.

Specifically,

Your firm cleans product contact equipment, glassware, and utensils with household cleaners after they are used for production of hazardous and potent drugs. There is no assurance that household cleaning detergent is effective in cleaning and removal of product and cleaning agent residue from shared production equipment, glassware, and utensils used in the production of hazardous and potent drugs to prevent cross-contamination.

A) There are no assurances product contact equipment, glassware, and utensils used during compounding of Hazardous Drugs such as testosterone and estrogen, are cleaned with a deactivation product sufficient to prevent cross contamination with other hazardous or non­hazardous compounds. Additionally, your firm has not demonstrated that utensils used in the compounding of hazardous compounds are delineated or discemable from any other equipment, glassware, and utensils used for the compounding of non-hazardous compounded drug products. ...

Read the full 483 (PDF on fda.gov)

Inspection Jun 28, 2017 to Jul 12, 2017: 1 observation

Firm on the cover
JD & SN I nc., Moses Lalce, ~ 98837 - 4623 Producer of non-ste rile dru g produ cts ­ ' T his document lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection or action with the FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above. The observations noted in this Form FDA are not an exhaustive listing of objectionable conditions. Under the law, your firm is responsible for conducting internal self-audits to identify and correct any and all violations of th e quality system requirements.
FEI number
3004603767
FDA district office on the cover
Bothell, WA 98021
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov); FDA also posts it as https://www.fda.gov/media/133109/download

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

Cleaning of production and processing areas, equipment and utensils used for the production of highly potent and hazardous drugs are inadequate to prevent cross contamination. For example:

A) <Redacte d B4> hoods have residual <Redacted B4> drug product on the work surfaces, walls and ceiling after end of production cleaning on 6/29/17. For example, the <Redacted B4> hood in the <Redacted B4> room have <Redacted B4> residual on the touoch screen of the <Redacted B4> balance, <Redacted B4> <Redacted B4> on the turn knob on the encapsulation machine, <Redacted B4> on the exterior of the encapsulation machine, and built-up in the grooves in the work table. Your current practice does not require the cleaning of the work surfaces prior to the start of production the following morning.

B) There is no assurance that household cleaning detergent is effective in cleaning and removal of drug residuals on shared production equipment and utensils used in the production of hazardous and potent drugs. ...

Read the full 483 (PDF on fda.gov)

Linked 483s whose text is not shown

State board of pharmacy records

State board of pharmacy records for Washington are not checked: the Department of Health’s open dataset on data.wa.gov lists individual credentials but not pharmacy licenses, and its enforcement column has been removed for now; the department’s provider search is an interactive search, which this index does not use.

This page restates FDA’s lists. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.